Trial reportEndoscopy2010
Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial.
Trial report in Endoscopy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years
National Registry for Radiofrequency Ablation in Patients With Barrett's Esophagus
A Prospective, Open Label Study: Safety and Efficacy of a New Ablation Catheter RFA (Radiofrequency Under EUS) Developed by TAEWOONG Company for the Treatment of Pancreatic Premalignant and Early Malignant Cyctic Lesions.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2013Pooled it
- Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.The American journal of gastroenterology · 2011Pooled it
- Trial
- Durability of radiofrequency ablation in Barrett's esophagus with dysplasia.Gastroenterology · 2011Trial
- Coexistent Eosinophilic Esophagitis and Dysplastic Barrett's Esophagus With Rapid Eosinophilic Infiltration of Neosquamous Mucosa After Radiofrequency Ablation.ACG case reports journal · 2024Article
- Atrial Flutter After Radiofrequency Ablation for Barrett's Esophagus: A Case Report.The American journal of case reports · 2023Article
- Barrett's esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies.World journal of gastrointestinal oncology · 2022Review
- Article
- State-of-the-art management of dysplastic Barrett's esophagus.Gastroenterology report · 2022Review
- Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment.Quantitative imaging in medicine and surgery · 2021Review
- Adaptive Boosting (AdaBoost)-based multiwavelength spatial frequency domain imaging and characterization for ex vivo human colorectal tissue assessment.Journal of biophotonics · 2020Article
- Quality indicators for Barrett's endotherapy (QBET): UK consensus statements for patients undergoing endoscopic therapy for Barrett's neoplasia.Frontline gastroenterology · 2020Article
- Real-time colorectal cancer diagnosis using PR-OCT with deep learning.Theranostics · 2020Article
- Radiofrequency Ablation, Where It Stands in Interventional Radiology Today.Seminars in interventional radiology · 2019Review
- The Angular Spectrum of the Scattering Coefficient Map Reveals Subsurface Colorectal Cancer.Scientific reports · 2019Article
- Endoscopic surveillance or ablation for Barrett's esophagus?Translational gastroenterology and hepatology · 2018Review
- Assessment of the radiofrequency ablation dynamics of esophageal tissue with optical coherence tomography.Journal of biomedical optics · 2017Article
- Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium.The American journal of gastroenterology · 2017Review
- Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis.Endoscopy international open · 2017Article
- Quality Indicators in Endoscopic Ablation for Barrett's Esophagus.Current treatment options in gastroenterology · 2017Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND STUDY
aimsThe AIM-II Trial included patients with nondysplastic Barrett's esophagus (NDBE) treated with radiofrequency ablation (RFA). Complete eradication of NDBE (complete response-intestinal metaplasia [CR-IM]) was achieved in 98.4 % of patients at 2.5 years. We report the proportion of patients demonstrating CR-IM at 5-year follow-up. PATIENTS AND
methodsProspective, multicenter US trial (NCT00489268). After endoscopic RFA of NDBE up to 6 cm, patients with CR-IM at 2.5 years were eligible for longer-term follow-up. At 5 years, we obtained four-quadrant biopsies from every 1 cm of the original extent of Barrett's esophagus. All specimens were reviewed by one expert gastrointestinal pathologist, followed by focal RFA and repeat biopsy if NDBE was identified. Primary outcomes were (i) proportion of patients demonstrating CR-IM at 5-year biopsy, and (ii) proportion of patients demonstrating CR-IM at 5-year biopsy or after the single-session focal RFA.
resultsOf 60 eligible patients, 50 consented to participate. Of 1473 esophageal specimens obtained at 5 years 85 % contained lamina propria or deeper tissue (per patient, mean 30 , standard deviation [SD] 13). CR-IM was demonstrated in 92 % (46 / 50) of patients, while 8 % (4 / 50) had focal NDBE; focal RFA converted all these to CR-IM. There were no buried glands, dysplasia, strictures, or serious adverse events. Kaplan-Meier CR-IM survival analysis showed probability of maintaining CR-IM for at least 4 years after first durable CR-IM was 0.91 (95 % confidence interval [CI] 0.77 - 0.97) and mean duration of CR-IM was 4.22 years (standard error [SE] 0.12).
conclusionsIn patients with NDBE treated with RFA, CR-IM was demonstrated in the majority of patients (92 %) at 5-year follow-up, biopsy depth was adequate to detect recurrence, and all failures (4 / 4, 100 %) were converted to CR-IM with single-session focal RFA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.